RSS   Newsletter   Contact   Advertise with us
Post Online Media

Immunomedics appoints Michael R. Garone as VP of finance

ImmunomedicsImmunomedics, Inc., a biopharmaceutical company, announced the appointment of Michael R. Garone as vice president of finance, and chief financial officer.
From 2007 to 2016, Mr. Garone was Chief Financial Officer for Emisphere.

Before joining Emisphere, he served as interim Chief Executive Officer and Chief Financial Officer of Astralis. Prior to that, he served 20 years at AT&T, where he held several positions including Chief Financial Officer of AT&T Alascom.

Mr. Garone received an MBA from Columbia University and a BS in mathematics from Colgate University.

Mr. Garone replaces Peter P. Pfreundschuh, who has resigned from the Company. He will serve as a consultant to the Company for the next few months.

Mr. Pfreundschuh joined Immunomedics as Vice President, Finance and Chief Financial Officer in September 2013. From November 2008 through June 2013, he was the Chief Financial Officer of CircuLite.

Prior to that, he was the Executive Director of Business Development and Licensing for AstraZeneca Pharmaceuticals.

Before AstraZeneca, Mr. Pfreundschuh served at Johnson and Johnson in a variety of capacities including Controller of the R&D division and Controller/Director of Marketing and Global Business Analytics, as well as Chief Financial Officer/Treasurer for 3 Dimensional Pharmaceuticals, which was acquired by Johnson and Johnson.

He has also held management positions at Alimenterics and American Standard Companies, and was a Senior Auditor at Ernst & Young.

A New Jersey Certified Public Accountant, Mr. Pfreundschuh received an MBA with a concentration in finance from Rider University, a BS in accounting from Rutgers University School of Business, and has continued his education through the Executive Strategic Marketing Program in Healthcare at the Kellogg School of Management at Northwestern University.




    We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

    Allow Cookies Privacy Policy